Expression of p27 and c-Myc by immunohistochemistry in breast ductal cancers in African American women

Publication date: Available online 5 April 2018
Source:Annals of Diagnostic Pathology
Author(s): Farhan Khan, Luisel J. Ricks-Santi, Rabia Zafar, Yasmine Kanaan, Tammey Naab
ObjectivesProteins p27 and c-myc are both key players in the cell cycle. While p27, a tumor suppressor, inhibits progression from G1 to S phase, c-Myc, a proto-oncogene, plays a key role in cell cycle regulation and apoptosis. The objective of our study was to determine the association between expression of c-Myc and the loss of p27 by immunohistochemistry (IHC) in the four major subtypes of breast cancer (BC) (Luminal A, Luminal B, HER2, and Triple Negative) and with other clinicopathological factors in a population of 202 African-American (AA) women.Materials and methodsTissue microarrays (TMAs) were constructed from FFPE tumor blocks from primary ductal breast carcinomas in 202 AA women. Five micrometer sections were stained with a mouse monoclonal antibody against p27 and a rabbit monoclonal antibody against c-Myc. The sections were evaluated for intensity of nuclear reactivity (1–3) and percentage of reactive cells; an H-score was derived from the product of these measurements.ResultsLoss of p27 expression and c-Myc overexpression showed statistical significance with ER negative (p < 0.0001), PR negative (p < 0.0001), triple negative (TN) (p < 0.0001), grade 3 (p = 0.038), and overall survival (p = 0.047). There was no statistical significant association between c-myc expression/p27 loss and luminal A/B and Her2 overexpressing subtypes.ConclusionIn our study, a statistically significant association between c-Myc expression and PTEN loss and the triple negative breast cancers (TNBC) was found in AA women. A recent study found that constitutive c-Myc expression is associated with inactivation of the axin 1 tumor suppressor gene. p27 inhibits cyclin dependent kinase2/cyclin A/E complex formation. Axin 1 and CDK inhibitors may represent possible therapeutic targets for TNBC.



https://ift.tt/2uOJL1p